Rheumatic mitral stenosis remains a health problem in developing countries. Progressive
fibrosis of the valves and myocardium is the main pathophysiology that plays an important
role. Dapagliflozin has various beneficial effects on the heart by increasing fibrosis,
reducing inflammation, and improving patients' quality of life. However, the role of this
therapy is unknown in patients with rheumatic mitral stenosis.